1. Home
  2. REFI vs LCTX Comparison

REFI vs LCTX Comparison

Compare REFI & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Chicago Atlantic Real Estate Finance Inc.

REFI

Chicago Atlantic Real Estate Finance Inc.

HOLD

Current Price

$9.35

Market Cap

240.1M

Sector

Real Estate

ML Signal

HOLD

Logo Lineage Cell Therapeutics Inc.

LCTX

Lineage Cell Therapeutics Inc.

HOLD

Current Price

$1.01

Market Cap

251.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
REFI
LCTX
Founded
2021
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
240.1M
251.4M
IPO Year
2021
1996

Fundamental Metrics

Financial Performance
Metric
REFI
LCTX
Price
$9.35
$1.01
Analyst Decision
Buy
Strong Buy
Analyst Count
5
7
Target Price
★ $15.13
$5.50
AVG Volume (30 Days)
190.0K
★ 1.5M
Earning Date
11-10-2026
11-05-2026
Dividend Yield
★ 20.00%
N/A
EPS Growth
★ N/A
N/A
EPS
★ 0.57
N/A
Revenue
★ $48,857,628.00
$14,556,000.00
Revenue This Year
$0.76
$4.38
Revenue Next Year
$7.89
$10.80
P/E Ratio
$16.50
★ N/A
Revenue Growth
N/A
★ 53.24
52 Week Low
$8.76
$0.88
52 Week High
$13.49
$2.09

Technical Indicators

Market Signals
Indicator
REFI
LCTX
Relative Strength Index (RSI) 40.14 52.82
Support Level N/A $0.89
Resistance Level $10.97 $1.05
Average True Range (ATR) 0.26 0.06
MACD 0.01 0.01
Stochastic Oscillator 50.00 74.16

Price Performance

Historical Comparison
REFI
LCTX

About REFI Chicago Atlantic Real Estate Finance Inc.

Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. The Company operates as one operating segment, and its primary investment objective is to provide attractive, risk-adjusted returns for stockholders over time, mainly through consistent current income (dividends and distributions) and secondarily, through capital appreciation. The company operates mainly within the USA itself.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.

Share on Social Networks: